JP2017513904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513904A5 JP2017513904A5 JP2016564173A JP2016564173A JP2017513904A5 JP 2017513904 A5 JP2017513904 A5 JP 2017513904A5 JP 2016564173 A JP2016564173 A JP 2016564173A JP 2016564173 A JP2016564173 A JP 2016564173A JP 2017513904 A5 JP2017513904 A5 JP 2017513904A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- target
- igf
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 17
- 239000000611 antibody drug conjugate Substances 0.000 claims 14
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 14
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 10
- -1 CD79 Proteins 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 229940125644 antibody drug Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 108700012439 CA9 Proteins 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 102100025221 CD70 antigen Human genes 0.000 claims 3
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims 3
- 108010055334 EphB2 Receptor Proteins 0.000 claims 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 3
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 3
- 101710088083 Glomulin Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 3
- 101000893701 Homo sapiens 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3 Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 3
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 3
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 102000003735 Mesothelin Human genes 0.000 claims 3
- 108090000015 Mesothelin Proteins 0.000 claims 3
- 102100023123 Mucin-16 Human genes 0.000 claims 3
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 3
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 3
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 3
- 101150047061 tag-72 gene Proteins 0.000 claims 3
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 108090000144 Human Proteins Proteins 0.000 claims 2
- 102000003839 Human Proteins Human genes 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 102000051957 human ERBB2 Human genes 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 125000006781 (C4-C10) cycloalkylcarbonyl group Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305621 | 2014-04-25 | ||
| EP14305621.6 | 2014-04-25 | ||
| PCT/EP2015/059052 WO2015162293A1 (en) | 2014-04-25 | 2015-04-27 | Antibody-drug-conjugate and its use for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513904A JP2017513904A (ja) | 2017-06-01 |
| JP2017513904A5 true JP2017513904A5 (enExample) | 2018-05-17 |
| JP6567551B2 JP6567551B2 (ja) | 2019-08-28 |
Family
ID=50630737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564173A Active JP6567551B2 (ja) | 2014-04-25 | 2015-04-27 | 抗体−薬物複合体および癌の処置のためのその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10314921B2 (enExample) |
| EP (2) | EP3607996B1 (enExample) |
| JP (1) | JP6567551B2 (enExample) |
| KR (1) | KR102459647B1 (enExample) |
| CN (1) | CN106470708B (enExample) |
| AU (1) | AU2015250761B2 (enExample) |
| BR (1) | BR112016024363A2 (enExample) |
| CA (1) | CA2946796C (enExample) |
| CY (1) | CY1122472T1 (enExample) |
| DK (1) | DK3134125T3 (enExample) |
| ES (1) | ES2764110T3 (enExample) |
| HR (1) | HRP20192254T1 (enExample) |
| HU (1) | HUE047952T2 (enExample) |
| LT (1) | LT3134125T (enExample) |
| MX (1) | MX378281B (enExample) |
| PL (1) | PL3134125T3 (enExample) |
| PT (1) | PT3134125T (enExample) |
| RS (1) | RS59799B1 (enExample) |
| RU (1) | RU2685259C2 (enExample) |
| SI (1) | SI3134125T1 (enExample) |
| WO (1) | WO2015162293A1 (enExample) |
| ZA (1) | ZA201607415B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| PL3134125T3 (pl) | 2014-04-25 | 2020-04-30 | Pierre Fabre Médicament | Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka |
| UA120364C2 (uk) * | 2014-04-25 | 2019-11-25 | Пьєр Фабр Медікамент | Кон'югат антитіла до igf-1r з лікарським засобом |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| EP3288593A1 (en) * | 2015-04-27 | 2018-03-07 | Pierre Fabre Médicament | Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer |
| RU2728568C2 (ru) * | 2015-10-26 | 2020-07-30 | Пьер Фабр Медикамент | Композиция для лечения рака, экспрессирующего igf-1r |
| US9669106B2 (en) * | 2015-10-26 | 2017-06-06 | Pierre Fabre Medicament | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer |
| BR112018016983A2 (pt) * | 2016-02-26 | 2018-12-26 | Jiangsu Hengrui Medicine Co., Ltd. | nova toxina e método de preparação de intermediário da mesma |
| KR102456433B1 (ko) * | 2016-03-02 | 2022-10-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
| CN105968038A (zh) * | 2016-05-09 | 2016-09-28 | 湖北华世通生物医药科技有限公司 | 二肽类化合物的盐酸盐及其制备方法 |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| SG10202110182PA (en) | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| WO2018217459A2 (en) * | 2017-05-23 | 2018-11-29 | Academia Sinica | Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy |
| US20210079039A1 (en) * | 2018-04-16 | 2021-03-18 | Avelas Biosciences, Inc. | Compositions and methods for the selective delivery of therapeutic and imaging agents |
| WO2019214492A1 (zh) * | 2018-05-11 | 2019-11-14 | 四川科伦博泰生物医药股份有限公司 | 抗her2抗体-药物偶联物在治疗癌症中的用途 |
| BR112021005655A2 (pt) | 2018-09-27 | 2021-06-29 | Pierre Fabre Medicament | ligantes à base de sulfomaleimida e conjugados correspondentes |
| EP3856229A1 (en) * | 2018-09-28 | 2021-08-04 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
| EP3735991A1 (fr) * | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| IL318992A (en) | 2022-05-02 | 2025-04-01 | Precirix N V | Cancer treatment through advance directives |
| CN118307677B (zh) * | 2023-01-09 | 2025-08-12 | 中国医学科学院医药生物技术研究所 | 一种针对间皮素的单克隆抗体及应用 |
| WO2025087401A1 (zh) * | 2023-10-27 | 2025-05-01 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69434136T2 (de) | 1993-10-01 | 2005-12-01 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin-derivate |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JP5290756B2 (ja) * | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
| US20090098115A1 (en) | 2006-10-20 | 2009-04-16 | Lisa Michele Crocker | Cell lines and animal models of HER2 expressing tumors |
| UA94628C2 (ru) * | 2006-10-27 | 2011-05-25 | Дженентек, Инк. | Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| AR065803A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| DK2842575T3 (da) * | 2008-03-18 | 2017-11-27 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| DK2276509T3 (en) | 2008-04-11 | 2016-09-19 | Seattle Genetics Inc | DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers |
| AU2010229192A1 (en) | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP5791707B2 (ja) | 2010-06-10 | 2015-10-07 | シアトル ジェネティックス， インコーポレイテッド | 新規アウリスタチン誘導体およびその使用 |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| ES3004351T3 (en) * | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| ES2543888T3 (es) | 2011-03-16 | 2015-08-25 | Seattle Genetics, Inc. | N-carboxialquil-auristatinas y su utilización |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US9796754B2 (en) | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| ES2898854T3 (es) * | 2011-05-27 | 2022-03-09 | Ambrx Inc | Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| EP2858676B1 (en) | 2012-06-07 | 2019-03-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| SG11201408161RA (en) * | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| KR102190832B1 (ko) | 2012-06-19 | 2020-12-15 | 암브룩스, 인코포레이티드 | 항cd70 항체 약물 컨쥬게이트 |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| EP2885321A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| PL3134125T3 (pl) | 2014-04-25 | 2020-04-30 | Pierre Fabre Médicament | Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka |
-
2015
- 2015-04-27 PL PL15720314T patent/PL3134125T3/pl unknown
- 2015-04-27 PT PT157203142T patent/PT3134125T/pt unknown
- 2015-04-27 HU HUE15720314A patent/HUE047952T2/hu unknown
- 2015-04-27 CN CN201580034144.1A patent/CN106470708B/zh active Active
- 2015-04-27 EP EP19195042.7A patent/EP3607996B1/en active Active
- 2015-04-27 ES ES15720314T patent/ES2764110T3/es active Active
- 2015-04-27 JP JP2016564173A patent/JP6567551B2/ja active Active
- 2015-04-27 RU RU2016145445A patent/RU2685259C2/ru active
- 2015-04-27 KR KR1020167031822A patent/KR102459647B1/ko active Active
- 2015-04-27 EP EP15720314.2A patent/EP3134125B1/en active Active
- 2015-04-27 LT LTEP15720314.2T patent/LT3134125T/lt unknown
- 2015-04-27 DK DK15720314.2T patent/DK3134125T3/da active
- 2015-04-27 US US15/306,404 patent/US10314921B2/en active Active
- 2015-04-27 AU AU2015250761A patent/AU2015250761B2/en not_active Ceased
- 2015-04-27 RS RS20191700A patent/RS59799B1/sr unknown
- 2015-04-27 HR HRP20192254TT patent/HRP20192254T1/hr unknown
- 2015-04-27 SI SI201531056T patent/SI3134125T1/sl unknown
- 2015-04-27 BR BR112016024363A patent/BR112016024363A2/pt not_active Application Discontinuation
- 2015-04-27 MX MX2016013999A patent/MX378281B/es unknown
- 2015-04-27 CA CA2946796A patent/CA2946796C/en active Active
- 2015-04-27 WO PCT/EP2015/059052 patent/WO2015162293A1/en not_active Ceased
-
2016
- 2016-10-27 ZA ZA2016/07415A patent/ZA201607415B/en unknown
-
2018
- 2018-01-31 US US15/885,220 patent/US10912841B2/en active Active
-
2019
- 2019-04-16 US US16/385,597 patent/US11219693B2/en active Active
- 2019-12-20 CY CY20191101344T patent/CY1122472T1/el unknown
-
2020
- 2020-10-28 US US17/083,010 patent/US11517625B2/en active Active
-
2021
- 2021-11-15 US US17/454,931 patent/US11918656B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513904A5 (enExample) | ||
| RU2016145445A (ru) | Конъюгат антитела и лекарственного средства и его применение для лечения рака | |
| JP2017513900A5 (enExample) | ||
| Safarzadeh Kozani et al. | Nanobody-based CAR-T cells for cancer immunotherapy | |
| RU2016145444A (ru) | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака | |
| IL295759A (en) | Transglutaminase mediated coupling | |
| JP2017522871A5 (enExample) | ||
| AU2016293606A1 (en) | Cysteine-substituted immunoglobulins | |
| JP2019509055A5 (enExample) | ||
| IL317587A (en) | Antibody against SIRPalpha | |
| IL278633B2 (en) | Immunoconjugates | |
| JP2017186337A5 (enExample) | ||
| JP2013505944A5 (enExample) | ||
| JP2023113685A (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| JP2011046732A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| WO2020102779A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2011519864A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JPWO2022170971A5 (enExample) | ||
| JP2013528569A5 (enExample) | ||
| JPWO2021194942A5 (enExample) |